Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb18087 (Tidutamab) +/- Pembrolizumab in Advanced MCC or SCLC
NCT04590781Phase 2Terminated
- Sponsor
- Xencor
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tidutamab in Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), sponsored by Xencor. Started May 2021; status: terminated.
02
Drugs
tidutamab
03
Conditions
Merkel cell carcinoma (MCC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04590781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590781.